Schlagwörter
Aktuelle Nachrichten
America
Aus Aller Welt
Breaking News
Canada
DE
Deutsch
Deutschsprechenden
Global News
Internationale Nachrichten aus aller Welt
Japan
Japan News
Kanada
Karte
Karten
Konflikt
Korea
Krieg in der Ukraine
Latest news
Map
Maps
Nachrichten
News
News Japan
Polen
Russischer Überfall auf die Ukraine seit 2022
Science
South Korea
Ukraine
Ukraine War Video Report
UkraineWarVideoReport
United Kingdom
United States
United States of America
US
USA
USA Politics
Vereinigte Königreich Großbritannien und Nordirland
Vereinigtes Königreich
Welt
Welt-Nachrichten
Weltnachrichten
Wissenschaft
World
World News

2 Kommentare
*Lisa Pham for Bloomberg News*
One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears flattened defiantly. A third rushes to greet visitors with a friendly nuzzle.
This isn’t a petting zoo. The furry beasts are in Belgium for work.
Scientists have discovered the potential of the animals’ antibodies to thwart multiple diseases, and now drug developers are collectively plowing billions of dollars into a field that may yield a fresh generation of life-changing medicines. The targets include some hard-to-treat conditions like cancer, nerve pain and a chronic skin ailment.
The llamas are a vital part of the experiment. In between dust baths and grazing, they get injections to trigger the production of their precious antibodies. The animals are some of the few to produce the tiny proteins, dubbed nanobodies, which scientists praise as easy to produce, manipulate and engineer.
“They have this Lego-like nature that you can just snap them together any way you want to, which is really unique,” says Mark Lappe, the chief executive of US biotech Inhibrx Biosciences Inc. “If you try to do that with regular antibodies, it’s wildly complex.”
The field is burgeoning, albeit quietly for now. A Sanofi drug for a rare autoimmune blood disorder was the first medicine developed using llama antibodies to hit the market. AstraZeneca Plc recently released results for an experimental medicine to treat another autoimmune dysfunction that could be a potential blockbuster. And US pharma giant Eli Lilly & Co. has partnered with Belgian biotech firm Confo Therapeutics to gain rights to a product exploring a new approach to pain management.
[Read the full story here.](https://www.bloomberg.com/news/features/2026-01-23/astrazeneca-sanofi-eli-lilly-eye-nanobodies-for-possible-new-treatments?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc2OTE2Mzg4NCwiZXhwIjoxNzY5NzY4Njg0LCJhcnRpY2xlSWQiOiJUOUFXS1pLSVAzSUgwMCIsImJjb25uZWN0SWQiOiJEMzU0MUJFQjhBQUY0QkUwQkFBOUQzNkI3QjlCRjI4OCJ9.Hi4bMC1iXcRGz0UMs0-wYcDn3Sc6Z-da9bezpsJ_L_s)
Do they just set them lose and see what they come back with?